[Treating essential hypertension. Are beta blockers still first choice?].
Universitätsklinikum Münster. rahn@uni-muenster.de
K H
KH
Rahn
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D017311:Amlodipine / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D001539:Bendroflumethiazide / Q000627:therapeutic use; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control; D017063:Outcome Assessment, Health Care; D020913:Perindopril / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000401:mortality / Q000517:prevention & control
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D017311:Amlodipine; D001262:Atenolol; D001539:Bendroflumethiazide; D020913:Perindopril